Lifespan Logo
Log in
Donate
New Peptide Puts the Brakes on Cellular Senescence
Pep 14 reversed aspects of aging in cells and skin samples.
Josh Conway
By
Josh Conway
June 26, 2023
0
Researchers publishing in the Nature journal npj aging have discovered a new peptide that might prevent cells from becoming senescent and possibly youthen human skin.
Senolytics and senotherapeutics
WHAT ARE SENOLYTICS? SENOTHERAPEUTICS FOR SENESCENT CELLS
Senolytics work by targeting one of several pro-survival pathways that senescent cells use to evade apoptosis and cling onto life. One of the challenges in dealing with senescent cells is that there are a number of different populations of these cells in our tissues and organs, each using different pro-survival pathways. It could be that multiple senolytic drugs need to be used to remove senescent cells using different pathways to survive.
Read More
The introduction to this paper includes a discussion of the harmful effects of senescent cells and different methods of dealing with them. Killing these cells through senolytics has become the standard method explored in research and development. However, these researchers note that as killing some senescent cell populations can lead to a loss of functions such as wound healing [1], preventing or reversing their senescence through other senotherapeutics might be a better approach [2].
Finding an effective peptide
Senotherapeutics have not been as heavily researched as senolytics, so these researchers sought to help bridge that gap by exploring a library of 164 peptides that are known not to be cytotoxic: they do not kill cells. They used fibroblast cells from a progeric human donor, more than half of which were positive for the senescence marker SA-ß-gal and had large quantities of the senescence-related enzyme ATRX [3] and senescence-related gene expression.
The researchers looked for the peptides that reduced the percentage of senescent cells, then re-analyzed to create a different database of 764 potential candidates. Of this large group, the researchers selected five with the least toxicity and greatest senotherapeutic potential. The best-performing one was Pep 14, a compound that does not closely resemble any other known protein. It was found to reduce multiple senescent markers, although gene expression (left) and an ELISA protein assay (right) did not fully agree with each other.
Pep 14
Pathways and tissue samples
A closer look at RNA pathways found that Pep 14 reversed many of the epigenetic alterations associated with aging. Signaling, longevity, and cellular senescence pathways were all affected in positive ways, which, interestingly, were largely different from rapamycin’s effects. Pep 14 was found to modulate part of the PP2A pathway, which these researchers discovered to be part of cellular senescence.
A close examination of cellular populations found that Pep 14 delayed and discouraged the transition into late senescence, decreasing their proportions in samples. However, it was not found to have any affect on autophagy nor any senolytic properties: it does not kill cells.
Samples of donor skin and 3D-grown skin tissues showed encouraging results even compared to rapamycin. Samples treated with Pep 14 had more organized layers and better skin thickness than rapamycin-treated or untreated samples, and aging biomarkers were also improved. A formula designed to sink into the skin was developed, and it was found to perform better than retinol, which is often used to treat skin aging.
Promising, but early stages
These experiments were performed in skin cells and tissue samples, not mice and certainly not people. It remains to be seen whether Pep 14 can be safely and effectively administered to living organisms at all and if it has effects on other parts of the body. However, these results show significant potential, and we look forward to preclinical experiments and possibly clinical trials of this promising compound.
OneSkin, which funded this study, is a corporate sponsor of Lifespan.io.
We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.
All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.
DONATE TODAY
SingleRecurring
CHOOSE AMOUNT
$10
USD
$25
USD
$50
USD
$100
USD
$1000
USD
-- Enter Amount --
DONATE
Literature
[1] Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., … & Campisi, J. (2014). An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Developmental cell, 31(6), 722-733.
[2] Kim, E. C., & Kim, J. R. (2019). Senotherapeutics: emerging strategy for healthy aging and age-related disease. BMB reports, 52(1), 47.
[3] Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., … & Koff, A. (2017). ATRX is a regulator of therapy induced senescence in human cells. Nature communications, 8(1), 386.
CategoryNews
Tags:Cellular Senescence, Epigenetic Alterations, Senolytics, Senotherapeutics
Previous Post
Next Post
About the author
Josh Conway
Josh Conway
Josh is a professional editor and is responsible for editing our articles before they become available to the public as well as moderating our Discord server. He is also a programmer, long-time supporter of anti-aging medicine, and avid player of the strange game called “real life.” Living in the center of the northern prairie, Josh enjoys long bike rides before the blizzards hit.
No Comments
Write a comment:
Comment
Name *
Email *
Your email address will not be published.
Enter your Phone
Confirm your Email
DONATE TODAY
SingleRecurring
CHOOSE AMOUNT
$10 USD
$25 USD
$50 USD
$100 USD
$1000 USD
-- Enter Amount --
DONATE
Ending Age-Related Diseases Box
Ending Age-Related Diseases
Where longevity research meets DeSci and Investment.
Get Tickets
News Categories
News Categories
Select Category
Recent Articles
Longevity and DeSci Recap – June 2023
Longevity and DeSci Recap – June 2023
Welcome to the premier edition of Lifespan.io’s newest release, the Longevity and DeSci Recap. Here, we’ll fill you in on the very latest interviews, insights, and research in the longevity biotech sphere, covering topics such as […]
Preserved Kidneys Rewarmed and Transplanted in Rats
Preserved Kidneys Rewarmed and Transplanted in Rats
For the first time in history, scientists have been able to freeze, preserve, rewarm, and transplant rat kidneys with a new method of organ cryopreservation […]
New Peptide Puts the Brakes on Cellular Senescence
New Peptide Puts the Brakes on Cellular Senescence
Researchers publishing in the Nature journal npj aging have discovered a new peptide that might prevent cells from becoming senescent and possibly youthen […]
Journal Club June 2023
Journal Club June 2023
For the Journal Club this month, at 12:00 Eastern time on Tuesday, June 27, we are taking a look at the recent paper that […]
Popular Topics
How Metabolic Syndrome Makes Aging Worse
How Metabolic Syndrome Makes Aging Worse
Metabolic syndrome drives many of the hallmarks of aging, and multiple hallmarks of aging drive metabolic syndrome in a vicious, accelerating cycle. Central obesity, […]
Are There More Urgent Issues Than Aging?
Are There More Urgent Issues Than Aging?
When you discuss any major issue, sooner or later someone will say that there are more urgent issues than whatever it is you’re advocating for. Sometimes it may […]
Telling Genuine DAOs and Scams Apart
No comments:
Post a Comment